ATE292625T1 - 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien - Google Patents

8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien

Info

Publication number
ATE292625T1
ATE292625T1 AT01992702T AT01992702T ATE292625T1 AT E292625 T1 ATE292625 T1 AT E292625T1 AT 01992702 T AT01992702 T AT 01992702T AT 01992702 T AT01992702 T AT 01992702T AT E292625 T1 ATE292625 T1 AT E292625T1
Authority
AT
Austria
Prior art keywords
substituted
benzazocines
methano
morphinanes
receptor binding
Prior art date
Application number
AT01992702T
Other languages
English (en)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Application granted granted Critical
Publication of ATE292625T1 publication Critical patent/ATE292625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT01992702T 2000-10-31 2001-10-31 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien ATE292625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443800P 2000-10-31 2000-10-31
PCT/US2001/045581 WO2002036573A2 (en) 2000-10-31 2001-10-31 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents

Publications (1)

Publication Number Publication Date
ATE292625T1 true ATE292625T1 (de) 2005-04-15

Family

ID=22922766

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01992702T ATE292625T1 (de) 2000-10-31 2001-10-31 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
AT03013544T ATE391712T1 (de) 2000-10-31 2001-10-31 4-arylpiperidine als opioidrezeptorbindende agenzien

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03013544T ATE391712T1 (de) 2000-10-31 2001-10-31 4-arylpiperidine als opioidrezeptorbindende agenzien

Country Status (9)

Country Link
US (9) US6784187B2 (de)
EP (3) EP1353909B1 (de)
JP (2) JP4340437B2 (de)
AT (2) ATE292625T1 (de)
AU (2) AU2713502A (de)
CA (1) CA2426942C (de)
DE (2) DE60133584T2 (de)
ES (3) ES2304477T3 (de)
WO (1) WO2002036573A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JPWO2004078177A1 (ja) * 2003-03-07 2006-06-08 東レ株式会社 薬物・物質依存治療薬
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7589103B2 (en) 2003-06-27 2009-09-15 Janssen Pharmaceutica N.V. Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators
EP1595541A1 (de) 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Verwendung von Opioid-Rezeptor Antagonisten zur Vorbeugung und/oder Behandlung von Krankheiten die im zusammenhang mit den Angrifftspunkt Calcineurin stehen
MXPA06013270A (es) * 2004-05-14 2007-04-23 Johnson & Johnson Compuestos de opioide carboxamido.
CA2574768A1 (en) 2004-08-05 2006-02-05 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
TW200621785A (en) * 2004-11-04 2006-07-01 Toray Industries Analgesic
US7262298B2 (en) 2004-11-05 2007-08-28 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
CN101119992A (zh) 2004-12-22 2008-02-06 詹森药业有限公司 三环δ阿片样物质调节剂
MX2007007626A (es) 2004-12-22 2008-01-28 Johnson & Johnson Moduladores delta-opioides triciclicos.
US7432257B2 (en) 2005-01-06 2008-10-07 Janssen Pharmaceutica N.V. Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2612491A1 (en) 2005-06-16 2006-12-28 Janssen Pharmaceutica N.V. Tricyclic opioid modulators
AU2006272773B2 (en) * 2005-07-21 2012-03-08 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
WO2009023567A1 (en) 2007-08-09 2009-02-19 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
US20100190817A1 (en) * 2008-07-21 2010-07-29 Rensselaer Polytechnic Institute Large substituent, non-phenolic amine opioids
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
CA2765678A1 (en) 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US10363251B2 (en) 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011119605A2 (en) 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
WO2012008984A1 (en) 2010-07-16 2012-01-19 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
EP2608670B1 (de) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Verfahren zur behandlung von durch antipsychotika induzierter gewichtszunahme
WO2012027564A1 (en) 2010-08-26 2012-03-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012088015A2 (en) * 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
CA2840643C (en) * 2011-06-29 2017-11-21 Alkermes, Inc. Peripherally acting opioid compounds
SMT201800664T1 (it) 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US10138207B2 (en) * 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US9688638B2 (en) 2013-11-27 2017-06-27 Nektar Therapeutics Opioid agonists and uses thereof
CA2948144A1 (en) * 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
TW201629026A (zh) 2015-02-02 2016-08-16 佛瑪治療公司 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (de) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) * 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4374139A (en) * 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) * 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) * 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0624095B2 (de) 1991-12-31 2005-07-20 Zymogenetics, Inc. Verfahren und zusammensetzungen zur verminderung von blutverlust
EP0632041A1 (de) * 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen Neue Morphin Derivate mit verbesserten analgetischen und narkotischen Eigenschaften
HUP9900974A3 (en) * 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
US7262298B2 (en) * 2004-11-05 2007-08-28 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
AU2006272773B2 (en) * 2005-07-21 2012-03-08 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents

Also Published As

Publication number Publication date
WO2002036573A3 (en) 2003-08-21
EP1359146A3 (de) 2004-04-14
US20040030138A1 (en) 2004-02-12
US20140275545A1 (en) 2014-09-18
DE60109960D1 (de) 2005-05-12
US20110207763A1 (en) 2011-08-25
ATE391712T1 (de) 2008-04-15
US8642615B2 (en) 2014-02-04
AU2713502A (en) 2002-05-15
WO2002036573B1 (en) 2003-09-25
US20170217977A1 (en) 2017-08-03
EP1944292A1 (de) 2008-07-16
EP1944292B9 (de) 2016-07-06
EP1353909A2 (de) 2003-10-22
US7265226B2 (en) 2007-09-04
US20050090519A1 (en) 2005-04-28
US20120302591A1 (en) 2012-11-29
DE60109960T2 (de) 2006-02-16
US8252929B2 (en) 2012-08-28
EP1359146A2 (de) 2003-11-05
US6887998B2 (en) 2005-05-03
DE60133584T2 (de) 2009-06-04
US20060030580A1 (en) 2006-02-09
JP2004522706A (ja) 2004-07-29
DE60133584D1 (de) 2008-05-21
US9932349B2 (en) 2018-04-03
US20030187009A1 (en) 2003-10-02
EP1359146B1 (de) 2008-04-09
JP2004137288A (ja) 2004-05-13
US7956187B2 (en) 2011-06-07
WO2002036573A2 (en) 2002-05-10
JP4340437B2 (ja) 2009-10-07
AU2002227135B2 (en) 2008-01-03
CA2426942A1 (en) 2002-05-10
ES2304477T3 (es) 2008-10-16
EP1944292B1 (de) 2016-02-17
US20090048447A1 (en) 2009-02-19
ES2572332T3 (es) 2016-05-31
EP1353909B1 (de) 2005-04-06
US6784187B2 (en) 2004-08-31
ES2239170T3 (es) 2005-09-16
CA2426942C (en) 2014-06-03

Similar Documents

Publication Publication Date Title
DE60109960D1 (de) 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien
ATE261038T1 (de) Fussbodenleiste
CY1108918T1 (el) Φαρμακευτικοι συνδυασμοι οξυκωδονης και ναλοξονης
IL182983A0 (en) 4-hydroxybenzomorphans
BR0103322A (pt) Processo de preparo e uso de nanopartìculas de metal nobre
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
DE60029857D1 (de) Lichtempfindliche Zusammensetzung und 1,3-dihydro-1-oxo-2H-Indenderivat
NO970142L (no) Heterocyklus-kondenserte morfin-derivater
EP2072082A3 (de) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3 sulfonamid als analgetikum
IL163829A0 (en) Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
FR2797655B1 (fr) Patte d'ancrage d'huisserie, notamment d'huisserie metallique de porte ou de portail
TR200003502T2 (tr) Bir Piperidin Maddesi P Antagonistini İçeren Mikroemülsiyon Prekonsantratları
DE69922918D1 (de) Neuropeptid Y Antagonisten
TR200402036T4 (tr) (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu
IT1315905B1 (it) Barra rotante blinda vano antirotazione dell'anta di infissi in genere
PL373082A1 (en) N,n'-disubstituted piperazine compounds and the use of the same as analgesics
IT1305404B1 (it) Disposizione e procedimento per accogliere, consegnare e posizionarestrutture reticolari in particolare pannelli d'acciaio per
ITMS960004U1 (it) Sistema integrato a gestione vocale per il miglioramento dell'attivita lavorativa delle singola persona
FR2830422B1 (fr) Pupitre d'ecriture portable
EP1584333A3 (de) Verwendung von Acetylcoenzyme A Inhibitoren zur Behandlung von Alzheimer
UA5151S (uk) Комплект меблевий «беатріс-1»
MD1136F1 (en) Verbanov antimycotic ointment
IT250566Y1 (it) Dispositivo di sicurezza e di regolazione dell'inclinazione in sediea sdraio pieghevoli
ITBO20000463A0 (it) Dispositivo di bloccaggio dell' anta di porte e finestre .
LU90024B1 (de) Vorrichtung gegen Ammoniakbildung in Stallungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties